Finch Therapeutics
Presence
Finch Therapeutics is a company listed under the stock ticker FNCH (US).
Executives
View the org chart displaying its 10 main executives
Most searched biographies at Finch Therapeutics
- Matthew Blischak, Chief Executive Officer and Director
- Susan Graf, Chairman of the Board
- Jeff Smisek, Director
Create your alert
to follow the executive moves at Finch Therapeutics.
Biotechnology
Finch Therapeutics has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Finch Therapeutics
- Press Releases — Finch Therapeutics
- Press Releases — Finch Therapeutics
- Finch Therapeutics to Participate in Upcoming June Investor Conferences — Finch Therapeutics
- Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference — Finch Therapeutics
- Press Releases — Finch Therapeutics
- Press Releases — Finch Therapeutics
- Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results — Finch Therapeutics
- Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022 — Finch Therapeutics
- Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND — Finch Therapeutics
- In big year for microbiome drugs, a small biotech sets the bar | BioPharma Dive
- View more press releases Close
Social media about Finch Therapeutics
- Finch Therapeutics on Wikipedia, Google News & Yahoo Finance
- Finch Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Matthew Blischak 
Call Finch Therapeutics at +1 617...
